Edition:
United States

Express Scripts Holding Co (ESRX.OQ)

ESRX.OQ on NASDAQ Stock Exchange Global Select Market

87.34USD
16 Aug 2018
Change (% chg)

-- (--)
Prev Close
$87.34
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,140,147
52-wk High
$87.68
52-wk Low
$55.80

Select another date:

Wed, Aug 15 2018

Photo

Express Scripts staking out million dollar gene therapies

Express Scripts Holding Co built a multi-billion enterprise pressuring drug companies to lower their prices for U.S. patients. Now it is quietly building a side business: getting paid to help drug companies dispense a new generation of high-priced drugs.

CORRECTED--Express Scripts staking out million dollar gene therapies

Aug 15 Express Scripts Holding Co built a multi-billion enterprise pressuring drug companies to lower their prices for U.S. patients. Now it is quietly building a side business: getting paid to help drug companies dispense a new generation of high-priced drugs.

RPT-FOCUS-Express Scripts staking out million dollar gene therapies

Aug 15 Express Scripts Holding Co built a multi-billion enterprise pressuring drug companies to lower their prices for U.S. patients. Now it is quietly building a side business: getting paid to help drug companies dispense a new generation of high-priced drugs.

Express Scripts staking out million-dollar gene therapies

Express Scripts Holding Co built a multi-billion enterprise pressuring drug companies to lower their prices for U.S. patients. Now it is quietly building a side business: getting paid to help drug companies dispense a new generation of high-priced drugs.

FOCUS-Express Scripts staking out million dollar gene therapies

Aug 15 Express Scripts Holding Co built a multi-billion enterprise pressuring drug companies to lower their prices for U.S. patients. Now it is quietly building a side business: getting paid to help drug companies dispense a new generation of high-priced drugs.

Icahn reverses position on Cigna-Express Scripts deal

Activist investor Carl Icahn said on Monday that he no longer intended to solicit proxies to vote against the $52 billion Cigna-Express Scripts deal, a turn around from his position last week when he urged the health insurer's shareholders to vote against it.

UPDATE 1-Icahn reverses position on Cigna-Express Scripts deal

Aug 13 Activist investor Carl Icahn said on Monday that he no longer intended to solicit proxies to vote against the $52 billion Cigna-Express Scripts deal, a turn around from his position last week when he urged the health insurer's shareholders to vote against it.

Cigna-Express Scripts deal gets backing from another proxy firm

Aug 13 Cigna Corp said Glass Lewis & Co on Monday recommended its shareholders vote in favour for the proposed $52 billion acquisition of pharmacy benefits manager Express Scripts, the second proxy advisory firm to support the deal.

Advisory firm ISS backs Cigna's Express Scripts buy

Shareholder advisory firm Institutional Shareholder Services Inc (ISS) on Friday recommended that Cigna Corp investors vote for the health insurer's $52 billion purchase of pharmacy benefits manager Express Scripts , a deal that has been opposed by activist investor Carl Icahn.

Advisory firm ISS backs Cigna's Express Scripts buy

Aug 10 Shareholder advisory firm Institutional Shareholder Services Inc (ISS) on Friday recommended that Cigna Corp investors vote for the health insurer's $52 billion purchase of pharmacy benefits manager Express Scripts, a deal that has been opposed by activist investor Carl Icahn.

Select another date: